Coastal Infusion Administers Ultomiris®

Ultomiris (ravulizumab-cwvz) is used to treat two rare and serious conditions called Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS). PNH is a blood disorder that occurs when abnormal blood cells called PNH cells destroy red blood cells, which can lead to a lack of oxygen in the body. aHUS is a rare genetic disorder that affects the blood vessels and can lead to serious damage to vital organs such as the kidneys and brain.

The active substance in Ultomiris, ravulizumab, is a monoclonal antibody designed to attach to the C5 complement protein. In PNH and aHUS, the complement proteins are over-active, causing the destruction of red blood cells in PNH, and the formation of blood clots in small blood vessels throughout the body (thrombotic microangiopathy) in aHUS. By blocking the C5 complement protein, Ultomiris prevents the immune system from damaging cells, thereby helping to control symptoms of these diseases.

What It Treats

• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Atypical Hemolytic Uremic Syndrome (aHUS)

Prescribed By

• Hemotologists
• Nephrologists

How it’s Administered

Ultomiris is administered by intravenous infusion. Ultomiris infusions take 30 minutes to one hour.

Frequency

Ultomiris is generally administered every four weeks after three loading doses at 14-day intervals.

Related Drugs

Soliris

Additional Resources

• Ultomiris Website
• Prescribing Information
• Co-Pay Assistance

The information on this page is compiled from a variety of online sources. Coastal Infusion has made every effort to verify its accuracy, but patients are advised to discuss any planned or current treatments with their doctor. Report inaccuracies